Scientech Research LLC’s Neurocrine Biosciences NBIX Stock Holding History

Scientech Research LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,848	Closed	-$546K	–	643
2025 Q4	$546K	Buy	+3,848	New	+$557K	0.34%	77
2025 Q1	–	Sell	-4,429	Closed	-$605K	–	730
2024 Q4	$605K	Sell	4,429 -3,076	-41%	-$380K	0.17%	235
2024 Q3	$865K	Buy	7,505 +5,989	+395%	+$821K	0.17%	235
2024 Q2	$209K	Sell	1,516 -2,958	-66%	-$406K	0.04%	526
2024 Q1	$617K	Buy	+4,474	New	+$611K	0.33%	83

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scientech Research LLC's NBIX Position: Q1 2026 in Review

Scientech Research LLC sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,848 shares — an estimated $546K sold.

Scientech Research LLC first reported a position in NBIX in Q1 2024 and held it in 5 quarters. The position peaked at $865K in Q3 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Scientech Research LLC reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Scientech Research LLC sold 3,848 Neurocrine Biosciences shares in Q1 2026, an estimated $546K.
Scientech Research LLC first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 5 quarters.
Scientech Research LLC's Neurocrine Biosciences position peaked at $865K in Q3 2024.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.